MFN2 and cardiomyopathy: This points to a feasible pathogenic mechanism of cardiomyopathy in IDM because higher expression of MFN2 during cardiac development could contribute to a decreased number of cardiomyocytes, secondary hypertrophy, and impaired diastolic and systolic function.